AU2022238365A1 - A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder - Google Patents
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder Download PDFInfo
- Publication number
- AU2022238365A1 AU2022238365A1 AU2022238365A AU2022238365A AU2022238365A1 AU 2022238365 A1 AU2022238365 A1 AU 2022238365A1 AU 2022238365 A AU2022238365 A AU 2022238365A AU 2022238365 A AU2022238365 A AU 2022238365A AU 2022238365 A1 AU2022238365 A1 AU 2022238365A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- treatment course
- degrees
- subsequent treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162501P | 2021-03-17 | 2021-03-17 | |
| US63/162,501 | 2021-03-17 | ||
| US202163284592P | 2021-11-30 | 2021-11-30 | |
| US63/284,592 | 2021-11-30 | ||
| PCT/US2022/020716 WO2022197901A1 (en) | 2021-03-17 | 2022-03-17 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022238365A1 true AU2022238365A1 (en) | 2023-09-21 |
Family
ID=81327141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022238365A Pending AU2022238365A1 (en) | 2021-03-17 | 2022-03-17 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240245711A1 (https=) |
| EP (1) | EP4308162A1 (https=) |
| JP (1) | JP2024510436A (https=) |
| KR (1) | KR20230158033A (https=) |
| AU (1) | AU2022238365A1 (https=) |
| BR (1) | BR112023018607A2 (https=) |
| CA (1) | CA3213744A1 (https=) |
| IL (1) | IL305858A (https=) |
| MX (1) | MX2023010728A (https=) |
| TW (1) | TW202300156A (https=) |
| WO (1) | WO2022197901A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20230372364A1 (en) * | 2020-10-01 | 2023-11-23 | Jeremy Hill | Method of treating gaba mediated disorders |
-
2022
- 2022-03-17 AU AU2022238365A patent/AU2022238365A1/en active Pending
- 2022-03-17 WO PCT/US2022/020716 patent/WO2022197901A1/en not_active Ceased
- 2022-03-17 EP EP22715444.0A patent/EP4308162A1/en active Pending
- 2022-03-17 IL IL305858A patent/IL305858A/en unknown
- 2022-03-17 US US18/550,724 patent/US20240245711A1/en active Pending
- 2022-03-17 MX MX2023010728A patent/MX2023010728A/es unknown
- 2022-03-17 JP JP2023554337A patent/JP2024510436A/ja active Pending
- 2022-03-17 KR KR1020237034937A patent/KR20230158033A/ko active Pending
- 2022-03-17 CA CA3213744A patent/CA3213744A1/en active Pending
- 2022-03-17 BR BR112023018607A patent/BR112023018607A2/pt unknown
- 2022-03-17 TW TW111109951A patent/TW202300156A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023018607A2 (pt) | 2023-10-24 |
| JP2024510436A (ja) | 2024-03-07 |
| WO2022197901A1 (en) | 2022-09-22 |
| CA3213744A1 (en) | 2022-09-22 |
| TW202300156A (zh) | 2023-01-01 |
| EP4308162A1 (en) | 2024-01-24 |
| IL305858A (en) | 2023-11-01 |
| KR20230158033A (ko) | 2023-11-17 |
| MX2023010728A (es) | 2024-02-12 |
| US20240245711A1 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240245711A1 (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder | |
| US20250339447A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| AU2022267304A1 (en) | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female | |
| US20240216395A1 (en) | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression | |
| KR20240148425A (ko) | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 | |
| US20230018765A1 (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| AU2022202218A1 (en) | Combination Therapy Using Acamprosate And D-Cycloserine | |
| WO2022061287A1 (en) | TREATMENT OF NF-κB-MEDIATED DISEASE | |
| CN117098554A (zh) | 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇 | |
| EP4447977A1 (en) | Neuroactive steroid for the treatment of huntington's disease | |
| WO2025046421A1 (en) | Methods of using factor b inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO SAGE THERAPEUTICS, LLC |